Your browser doesn't support javascript.
loading
Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?
Zecca, Chiara; Bellavia, G; Brambilla, L; Gutierrez, L P; Gerardi, C; Fiori, A M; Bernardini, L R; Camera, G; Disanto, G; Petrini, L; Perugini, J; Antozzi, C G; Torri Clerici, V; Bellino, A; Confalonieri, P A; Gobbi, C; Mantegazza, R E; Rossi, S.
Afiliação
  • Zecca C; Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland. chiara.zecca@eoc.ch.
  • Bellavia G; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy. chiara.zecca@eoc.ch.
  • Brambilla L; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Gutierrez LP; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Gerardi C; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Fiori AM; IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
  • Bernardini LR; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Camera G; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Disanto G; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Petrini L; Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland.
  • Perugini J; Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland.
  • Antozzi CG; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Torri Clerici V; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Bellino A; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Confalonieri PA; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Gobbi C; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
  • Mantegazza RE; Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland.
  • Rossi S; Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
CNS Drugs ; 32(7): 653-660, 2018 07.
Article em En | MEDLINE | ID: mdl-29949101
ABSTRACT

BACKGROUND:

Glatiramer acetate (GA) 20 mg/day (GA20) is associated with immediate post-injection reactions (PIRs). For convenience of use, approved GA 40 mg three times weekly (GA40) delivers a similar weekly dose. The dose and concentration of a single GA40 injection are, however, twice as high as for GA20, and post-injection adverse events may differ. Cases of atypical PIRs to GA40 prompted us to systematically monitor such events.

OBJECTIVE:

The aim was to characterize atypical PIRs in multiple sclerosis (MS) patients treated with GA40.

METHODS:

Clinical practice data were prospectively collected in consecutive relapsing-remitting MS patients. Descriptive statistics for categorical and continuous variables, Mann-Whitney and Chi-squared tests for baseline comparisons, and Cox regression models for association of variables to first atypical PIRs were applied.

RESULTS:

Forty-six out of 173 patients (26.6%) given GA40 experienced any PIRs. Of those, 38 (22.0%) had atypical, 14 (8.1%) had combined typical and atypical, and 26 (15.0%) had recurrent atypical PIRs, most frequently shivering (13.3%) and nausea/vomiting (8.1%). Compared to typical PIRs, onset of atypical PIRs was significantly delayed (median 30 vs 1 min, p < 0.0001), and their median duration longer (median 120 vs 6 min, p = 0.00013). Previous exposure to GA20 was associated with a lower risk of atypical PIRs [hazard ratio (HR) = 0.35, 95% confidence interval (CI) 0.17-0.72, p = 0.0039]. Patients experiencing PIRs with GA20 were at elevated risk for atypical PIRs with GA40 (HR = 5.75, 95% CI 1.66-19.94, p = 0.0059).

CONCLUSIONS:

Atypical PIRs with GA40, especially gastrointestinal symptoms and/or fever/shivering, had a delayed onset and occurred in a significant proportion of our patients. Their real prevalence should be assessed in appropriately designed studies accounting for  nocebo responses. Initial dose titration might reduce PIR frequency.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Acetato de Glatiramer / Imunossupressores Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Acetato de Glatiramer / Imunossupressores Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article